These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29171774)

  • 21. Apremilast as a treatment for psoriasis.
    Shutty B; West C; Pellerin M; Feldman S
    Expert Opin Pharmacother; 2012 Aug; 13(12):1761-70. PubMed ID: 22712800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral Psoriasis Therapies.
    James J; Otto T; Gao J; Porter ML
    Dermatol Clin; 2024 Jul; 42(3):357-363. PubMed ID: 38796267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Song GG; Lee YH
    Clin Drug Investig; 2019 May; 39(5):421-428. PubMed ID: 30806969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic development in psoriasis.
    Sobell JM; Leonardi CL
    Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S69-72. PubMed ID: 25268599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
    Hsu L; Armstrong AW
    J Immunol Res; 2014; 2014():283617. PubMed ID: 24883332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A; Mahmood F; Wittmann M; Helliwell P
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
    Qiu Q; Feng Q; Tan X; Guo M
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
    [No Abstract]   [Full Text] [Related]  

  • 35. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
    Nash P; Kerschbaumer A; Dörner T; Dougados M; Fleischmann RM; Geissler K; McInnes I; Pope JE; van der Heijde D; Stoffer-Marx M; Takeuchi T; Trauner M; Winthrop KL; de Wit M; Aletaha D; Baraliakos X; Boehncke WH; Emery P; Isaacs JD; Kremer J; Lee EB; Maksymowych WP; Voshaar M; Tam LS; Tanaka Y; van den Bosch F; Westhovens R; Xavier R; Smolen JS
    Ann Rheum Dis; 2021 Jan; 80(1):71-87. PubMed ID: 33158881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update on the safety of apremilast for the treatment of plaque psoriasis.
    Shavit E; Shear NH
    Expert Opin Drug Saf; 2020 Apr; 19(4):403-408. PubMed ID: 32182143
    [No Abstract]   [Full Text] [Related]  

  • 37. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
    Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
    Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tofacitinib for the treatment of psoriasis.
    Galluzzo M; D'Adamio S; Servoli S; Bianchi L; Chimenti S; Talamonti M
    Expert Opin Pharmacother; 2016 Jul; 17(10):1421-33. PubMed ID: 27267933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On- and Off-Label Uses of Apremilast in Dermatology.
    Plachouri KM; Georgiou S
    Acta Dermatovenerol Croat; 2020 Dec; 28(3):171-179. PubMed ID: 33422172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New targets in psoriatic arthritis.
    Braun J
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.